On July 25, 2017, Fredrik Hieronymus et al published a meta-analysis in Molecular Psychiatry. The study is titled Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression. Elias Eriksson, PhD, Head of the Department of Pharmacology, University of Gothenburg, Sweden, is the principal… Continue Reading
The FDA: The Fox Guards the Hen House
In their Fall 2013 issue, the Journal of Law, Medicine, and Ethics published a symposium of papers by members of the Harvard’s Edmond J. Safra Center for Ethics. The symposium was called Institutional Corruption and Pharmaceutical Policy. The symposium focuses on pharmaceutical products generally, but all the material is relevant and important in the context… Continue Reading
Sluggish Cognitive Tempo – A New Diagnosis?
On April 11, 2014, journalist Alan Schwarz (brief bio here) published an article in the New York Times on this topic, titled Idea of New attention Disorder Spurs Research, and Debate. Alan has written extensively on the rising rates of the condition known as ADHD, and on the abuse of the drugs that are used… Continue Reading
Revitalizing Psychiatric Therapeutics?
In January of this year, Steven Hyman MD, former Director of NIMH and currently a leading psychiatric researcher at MIT and Harvard, published Revitalizing Psychiatric Therapeutics in Neuropsychopharmacology. The article is in the journal’s commentary section and is essentially an opinion piece. Here’s Dr. Hyman’s summary: “Despite high prevalence and enormous unmet medical need, the… Continue Reading
- Next Page »